Cell/Gene Tx channel feed

Evotec ends gene ther­a­py busi­ness, shuts down fa­cil­i­ty in Aus­tria

Last year
Pharma
Manufacturing

Bris­tol My­er­s' CAR-T ther­a­py Breyanzi adds fol­lic­u­lar lym­phoma to list of ap­provals

Last year
Pharma
FDA+

Aim­ing to de­cen­tral­ize CAR-T man­u­fac­tur­ing, Gala­pa­gos part­ners with largest US blood sup­ply net­work

Last year
Manufacturing

FDA of­fers more clar­i­ty on safe­ty test­ing for cell ther­a­pies

Last year
FDA+

Ex­ci­sion Bio­Ther­a­peu­tics’ at­tempt to gene ed­it HIV dis­ap­points. The com­pa­ny will now re­vamp vec­tor: #AS­GCT24

Last year
R&D

Sci­en­tists and star­tups re­veal new gene in­ser­tion tech­niques, though much re­mains be­hind closed doors: #AS­GCT24

Last year
Startups
R&D

Tessera un­veils promis­ing in vi­vo gene edit­ing treat­ment for sick­le cell in an in­creas­ing­ly com­pet­i­tive field: #AS­GCT24

Last year
R&D

Across two clin­i­cal tri­als, gene ther­a­py re­stores hear­ing in chil­dren deaf since birth: #AS­GCT24

Last year
R&D

Blue­bird bio starts 15 pa­tients on its three mul­ti­mil­lion-dol­lar gene ther­a­pies

Last year
Pharma

Free­line un­veils ear­ly ef­fi­ca­cy sig­nal for Gauch­er gene ther­a­py: #AS­GCT24

Last year
R&D

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Last year
China
In Focus

Ver­tex touts Cas­gevy sick­le cell launch as blue­bird makes progress with ri­val Lyf­ge­nia

Last year
Pharma

UPenn and Stan­ford analy­sis finds no sec­ondary can­cer cas­es di­rect­ly due to CAR-T

Last year
R&D

As­traZeneca ex­pands stake in cell and gene ther­a­py part­ner Cel­lec­tis

Last year
Financing
Pharma

Ex­clu­sive: New York biotech de­buts with $16M to find new ways to make sol­id can­cer cell ther­a­pies

Last year
Financing
Startups

ICER push­es back on FDA's po­ten­tial con­ver­sion of Sarep­ta's gene ther­a­py to full ap­proval

Last year
Pharma
FDA+

Ex­clu­sive: Spark co-founder launch­es new CNS gene ther­a­py biotech with $54M

Last year
Financing
Startups

FDA de­ci­sion on Sarep­ta’s Duchenne gene ther­a­py could come ear­li­er than ex­pect­ed

Last year
R&D
FDA+

Epi­ge­net­ic edit­ing start­up Chro­ma lays off staff, fo­cus­ing on reach­ing the clin­ic

Last year
People

Astel­las taps Po­sei­da for sec­ond CAR-T deal fo­cused on sol­id tu­mors

Last year
Deals

Prime Med­i­cine re­ceives FDA clear­ance to run first prime edit­ing clin­i­cal tri­al

Last year
R&D
FDA+

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

Last year
Pharma

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Last year
Pharma
FDA+

Astel­las' Friedre­ich’s atax­ia gene ther­a­py cleared for clin­i­cal study af­ter ear­li­er ver­sion stum­bled

Last year
R&D
First page Previous page 6789101112 Next page Last page
A service from the Financial Times